ARS Pharmaceuticals (SPRY) Projected to Post Quarterly Earnings on Wednesday

ARS Pharmaceuticals (NASDAQ:SPRY) is projected to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect ARS Pharmaceuticals to post earnings of ($0.50) per share and revenue of $22.31 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.42). The firm had revenue of $28.09 million for the quarter, compared to the consensus estimate of $25.58 million. ARS Pharmaceuticals had a negative return on equity of 100.29% and a negative net margin of 203.25%. On average, analysts expect ARS Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ARS Pharmaceuticals Stock Up 2.3%

NASDAQ SPRY opened at $9.03 on Wednesday. The stock has a fifty day moving average of $8.41 and a 200-day moving average of $9.36. The stock has a market capitalization of $896.68 million, a P/E ratio of -5.16 and a beta of 0.93. ARS Pharmaceuticals has a 52 week low of $6.66 and a 52 week high of $18.90. The company has a debt-to-equity ratio of 1.47, a quick ratio of 7.06 and a current ratio of 7.28.

Hedge Funds Weigh In On ARS Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. boosted its holdings in ARS Pharmaceuticals by 52.8% during the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock worth $91,000 after buying an additional 1,803 shares during the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of ARS Pharmaceuticals in the 4th quarter valued at about $65,000. BNP Paribas Financial Markets raised its position in shares of ARS Pharmaceuticals by 58.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,097 shares of the company’s stock valued at $106,000 after acquiring an additional 2,245 shares during the period. Russell Investments Group Ltd. boosted its stake in ARS Pharmaceuticals by 197.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock worth $67,000 after acquiring an additional 4,427 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in ARS Pharmaceuticals during the 3rd quarter worth approximately $82,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on SPRY shares. Weiss Ratings cut ARS Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Northland Securities initiated coverage on ARS Pharmaceuticals in a report on Thursday, April 9th. They set an “outperform” rating and a $25.00 price objective for the company. Zacks Research upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Leerink Partners set a $26.00 target price on shares of ARS Pharmaceuticals and gave the company an “outperform” rating in a research note on Tuesday, March 10th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, ARS Pharmaceuticals has a consensus rating of “Hold” and an average price target of $28.25.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.